Champignon Brands Inc (CSE:SHRM) (FRA:496) (OTCQB:SHRMF) announced Monday the appointment of Stephen Brooks as its new chief financial officer and Peter Rizakos as its new general counsel.
In a statement, the company said the two appointments complete the company's new top management team put into place by CEO Dr Roger McIntyre and the board of directors.
"These new management additions ready us for the future where the company's clinical products and services will help meet the enormous public need that is creating significant public demand for improved, ketamine-based treatments that are capable of rapid response in persons with depression," Dr McIntyre said.
READ: Champignon Brands says review of bipolar disorders confirms early diagnosis and treatment can improve patient quality of life
The company said Brooks is a seasoned finance professional with over 25 years of experience across a range of industries including telecommunications, sports, entertainment, media, and retail.
He was formerly CFO of Sim International, a television and movie service provider, CFO of the Ottawa Senators NHL hockey club, and senior vice president of business operations for the Toronto Blue Jays and Rogers Centre. He also spent several years in senior finance roles with Rogers Communications Inc and Rogers Media Inc, including having responsibility for US and Canadian public reporting requirements.
Champignon said that Rizakos has 30 years of experience as a corporate and securities lawyer and as an executive in a variety of roles in both established and early-stage businesses. Most recently, he was president and CEO of a private mining company and general counsel for Marret Asset Management Inc. He was also a top legal officer for one of Canada's leading investment fund companies.
Furthermore, Champignon said that Chris Hobbs, who was named interim CFO on December 8 pending the recruitment of a new CFO, remains with the company as a special adviser to CFO Brooks with regards to the British Columbia Securities Commission (BCSC) continuous disclosure review and cease trade order (CTO).
The company said its growth strategy is international in scope and is proceeding even while it works with the BCSC toward the conclusion of the continuous disclosure review, the lifting of the CTO, and the resumption of trading on the Canadian Securities Exchange.
Dr McIntyre noted Champignon's depression clinic network continues to emerge with current and imminent openings of treatment centres in Toronto, Ottawa, and Montreal. The expansion of the network will continue through the company’s Canadian Rapid Treatment Centre of Excellence (CRTCE).
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
